SCHEMBL13034867

SCHEMBL13034867

CNS(=O)(=O)c1ccc(NS(=O)(=O)CC(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
PGR P06401 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 1/20 0.46
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA12 O43570 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA13 Q8N1Q1 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
DPP4 P27487 1/20 0.44
DPP7 Q9UHL4 1/20 0.44
KIF11 P52732 2/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13035763 0.81 HPGD (0.63) ALDH1A1SMN1; SMN2GAACA1CA2
SCHEMBL10192135 0.80 PGR (0.51) ALDH1A1PGRSMN1; SMN2GAACA1
SCHEMBL10623902 0.78 CA2 (0.66) ALDH1A1SMN1; SMN2GAACA1CA2
SCHEMBL13797611 0.77 PGR (0.49) ALDH1A1PGRSMN1; SMN2GAACA1
SCHEMBL14466586 0.76 PGR (0.48) ALDH1A1PGRSMN1; SMN2CA1CA2
SCHEMBL95330 0.76 PGR (0.48) PGRSMN1; SMN2CA1CA2DPP4
SCHEMBL10622850 0.75 KMT2A (0.47) ALDH1A1PGRCA1CA2KIF11
SCHEMBL6798952 0.73 PGR (0.46) ALDH1A1PGRSMN1; SMN2CA1CA2
SCHEMBL12678580 0.73 PGR (0.46) PGRSMN1; SMN2KIF11LMNAHTT
SCHEMBL4129798 0.73 PGR (0.48) PGRSMN1; SMN2CA1CA2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286365-A1 PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME AMYLIN PHARMACEUTICALS, INC. (US) 2010-11-11 US disclosed
US-20090186817-A1 PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME AMYLIN PHARMACEUTICALS, INC. (US) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186817-A1 PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME DNPEP, PEPD, VIP ALDH1A1 2598/4885PGR 4308/4885SMN1; SMN2 3541/4885
US-20100286365-A1 PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME DNPEP, PEPD, VIP ALDH1A1 2481/4885PGR 4343/4885SMN1; SMN2 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.